Gland Pharma (GLAND) — Board Meeting

📢 Key Event
Board approved unaudited consolidated financial results for Q1 FY27

🔄 What Changed
Revenue grew 20% YoY to ₹18,003 million; PAT margin improved to 18%; exceptional item of ₹243.46 million recognized

🔮 What's Next
CDMO partnership targeting USD 90-100 million annual revenue by 2029

💡 Investor Takeaway
Strong Q1 growth and strategic partnerships signal positive momentum for future revenue expansion

Gland Pharma Limited approved unaudited consolidated financial results for Q1 FY27 (quarter ended June 30, 2026) on August 10, 2026, following a limited review by Deloitte Haskins & Sells. The results show revenue of ₹18,003 million, PAT of ₹3,170 million, and a 20% YoY revenue growth driven by CDMO and B2B segments. An exceptional item of ₹243.46 million was recorded for gratuity liabilities under new Labour Codes. The auditor issued an unmodified opinion, confirming no material misstatements. The company highlighted strategic partnerships and pipeline progress during the earnings call scheduled for 6:30 PM IST.

📄 View Original Announcement (PDF)

📊 Stock Analysis — GLAND ✨ Ask AI About This

About Gland Pharma Limited (GLAND)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹47,316.21 Cr P/E: 41.9 ROE: 10.9% ROCE: 15.2% Div Yield: 0.70%

View full GLAND stock details →

📡 Get AI alerts when GLAND files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLAND — Free

💡 Ask AI about this filing

"What is the expected timeline for CDMO revenue generation?" "How will the exceptional item impact future profitability?" "What is the status of the liposomal product pipeline?"

Ask AI Free →

📊 More GLAND filings

See all GLAND filings →

🔥 Also filed on 10 August 2026

TIMKEN Timken India Limited Financial Results DOMS DOMS Industries Limited Corporate Action HGS Hinduja Global Solutions Limited Financial Results SUNDRMFAST Sundram Fasteners Limited Financial Results AMJLAND Amj Land Holdings Limited Annual Report KANSAINER Kansai Nerolac Paints Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLAND files new disclosures

Track GLAND filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLAND — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd